Teams developing molecular diagnostic assays may need to move from exploratory oligo orders to repeated purchases under a stable specification. This guide concerns research-use oligonucleotides and materials supplied for IVD assay development; it does not describe a finished clinical diagnostic product. The purchasing question is whether the required sequences can be ordered, documented, compared across lots, and supplied as development needs change. Buyers should agree on those expectations with the synthesis provider before placing a larger or recurring order.
“Large scale” has no useful standalone number without a unit and a product definition. A buyer should separate the nominal synthesis scale per oligo from the final amount delivered after purification, the quantity needed per lot, the number of distinct sequences, and the anticipated volume over repeat orders. These figures can lead to different manufacturing and packaging discussions.
For example, a program may require more material of one approved probe, or smaller amounts of many sequences for assay development. Another may need frequent replenishment of a fixed primer set. These are different supply problems even if the annual quantity appears similar. In the first supplier discussion, give both the next required delivery and a forecast of later orders, with units and dates for each.
Ask the supplier which quantity is quoted as synthesis scale and which is the expected delivered amount. Where a project uses mass units, do not convert a nominal molar synthesis scale into a guaranteed mass delivery without the specific sequence, modification, processing yield, and agreed specification.
Once assay development narrows the candidates, give each selected oligo an approved identifier and version. The working specification should cover the 5′ to 3′ sequence, modification identities and positions, purification, quantity and unit, delivery format, and the QC records requested. The purchaser should identify which fields cannot change without review.
A specification lock is an agreement about what to order and assess; it does not mean the assay can never change. It gives both teams a clear reference for a later inquiry and makes it possible to distinguish a true repeat order from a revised design. Keep the approval date and owners of technical and purchasing decisions with the specification.
Define the attributes and acceptance criteria relevant to the development workflow, then agree on how the supplier will report them for each lot. Ask whether the available documentation includes an order or lot identifier, stated amount, purification information, and the analytical results applicable to the particular oligo. A certificate of analysis should be requested only with the fields actually available for that service.
When comparing lots, use the same agreed measures, methods, and reporting format where feasible. Record the purchaser’s own incoming assessment separately from supplier testing. Supplier QC evaluates agreed material characteristics; the assay developer remains responsible for studying how a lot performs in its specific assay and for making any downstream suitability decisions.
Describe verification as evidence about oligo identity and specified quality attributes rather than proof that every molecule has a perfectly correct sequence. Discuss which analytical options are appropriate for the oligo and what each result can and cannot establish.
A repeated purchase should be evaluated against the approved specification and the same defined acceptance approach. A useful comparison may include reported quantity, purity or analytical profile, modification information, packaging, and any observations during incoming use, where these measures apply. If performance varies, retaining the lot identification and documents helps the development team investigate what changed.
Ask the supplier how a new production lot will be identified and what supporting records can be provided. Do not assume that two shipments are interchangeable solely because they share a product name. Buyers with particularly sensitive assays should decide in advance what additional internal checks they will perform when a new lot arrives.
A change in sequence, label, purification, amount, packaging, or an agreed QC requirement can affect a previously approved request. Establish who can propose a change, how it will be documented, and who approves the new version before manufacturing. For a repeat order, refer to the approved version rather than a conversational description of “the same primers as last time.”
Ask how the supplier communicates relevant changes to a confirmed order and how a buyer should submit a revised requirement. Keep a record of the original and revised specification, the reason for the update, the decision, and which subsequent orders use the new version. The process should match the actual service agreement; it should not imply a supplier change-control system that has not been confirmed.
Packaging affects how a development team receives, identifies, aliquots, and uses an oligo. Discuss whether it needs dry or solution delivery, separate aliquots, a plate map, a target concentration, or labeling compatible with its receiving process. State the format alongside the required final amount: a single bulk tube and multiple smaller aliquots can create very different laboratory work even when the total amount is identical.
For recurring supply, confirm how packaging instructions and labeling will be carried into later orders. Ask for any handling or storage information needed to support the receiving workflow, and decide internally how samples and retained records will be tracked.
Provide a forecast with an expected quantity, unit, number of sequences, desired delivery window, and an indication of how certain the demand is. Update it when development milestones change. This helps frame a discussion about lead times, order size, packaging, and how much notice a recurring purchase may require; it is not a guarantee of future volume.
When evaluating suppliers, ask how they handle revised forecasts, what lead time applies to a confirmed specification, and how they will communicate a supply constraint. Confirm any commitments in a written quotation or supply arrangement. Avoid assuming that a successful first delivery by itself establishes capacity for every future quantity or schedule.
| Buyer question | Evidence or agreement to request |
|---|---|
| What quantity is being quoted? | Synthesis scale, expected final amount per lot, unit, and delivery cadence |
| What stays the same? | Approved specification and version for each sequence |
| How are lots assessed? | Applicable QC methods, reported attributes, acceptance approach, and available COA fields |
| What happens when something changes? | Submission, review, approval, and versioning steps |
| How will material arrive? | Packaging, labeling, aliquots or plate format, and handling details |
| Can future demand be discussed? | Forecast update process, lead time, and documented supply terms |
Comparing suppliers on these fields provides a clearer cost picture than comparing a price per oligo without the same quantity basis, QC scope, and delivery format. Identify which requests are mandatory for the current development phase and which are future options. Ask the supplier to mark any item it cannot confirm.
Scaling an oligo supply request for IVD development starts with precise units and an approved material specification. Lot records, change decisions, packaging, and reorder forecasts then make later purchases easier to evaluate. The next step is to send the supplier the required sequences, quantity per delivery, forecast, and requested QC and documentation, and obtain a written response identifying what the proposed service can provide.
No. State the unit and distinguish nominal synthesis scale from expected final delivery, per-lot demand, and recurring demand. Ask the supplier to confirm the available range for the exact product and service.
Approve a sequence ID and version together with modifications, purification, required final amount, format, and any agreed QC and documentation requirements. Flag proposed changes before a new order is accepted.
Compare the lot identifiers, agreed reported attributes, and available analytical records, then follow the development team’s own incoming assessment plan. The same product name alone is not a complete comparison.
No. Supplier QC concerns specified characteristics of the supplied material. The assay developer assesses performance and suitability for its own intended development workflow.
Share approved specifications, expected quantity and unit per delivery, the number of sequences, anticipated reorder dates, packaging needs, and forecast uncertainty. Agree separately on lead time and any future supply commitments.
Stay updated with the latest industry news and expert insights.
Subscribe now to receive:
● Industry updates
● Exclusive expert insights and analysis
Enter your email to stay ahead!
